1734MO Hypoxic bladder cancers have a poorer outcome following hypofractionated vs conventionally fractionated radiotherapy in the BC2001 and BCON randomised trials

Abstract

Radical treatment for muscle-invasive bladder cancer (MIBC) involves radiotherapy with radiosensitiser or cystectomy currently selected subjectively (patient/clinician preference). The West 24-gene bladder cancer hypoxia signature predicted benefit from hypoxia-modifying radiosensitisation (carbogen+nicotinamide, CON) in BCON trial. The BC2001 trial showed combining chemotherapy (5-FU, mitomycin-C) with radiotherapy (RT) improves loco-regional progression free survival. Both BCON and BC2001 allowed conventional (62Gy/32 fractions) or hypofractionated (55Gy/20 fractions) RT.